Increased μ-opioid Receptor Expression in Metastatic Lung Cancer

Overview

Journal Br J Anaesth

Publisher Elsevier

Specialty Anesthesiology

Date 2014 Jun 13

PMID 24920011

Citations 63

Authors

P A Singleton

T Mirzapoiazova

R Hasina

R Salgia

J Moss

Affiliations

Soon will be listed here.

Abstract

Background: We and others have previously demonstrated that the μ-opioid receptor (MOR) is overexpressed in several human malignancies. There is a seven-fold increase in MOR in cell lines of human lung cancer. In animal models, overexpression of MOR promotes tumour growth and metastasis. We, therefore, examined whether MOR expression is increased in metastatic lung cancer.

Methods: In this study, we examined the association between MOR expression and metastasis in archived biopsy samples from patients with lung cancer. Paraffin-embedded patient material was stained using MOR antibody and scored qualitatively by two independent pathologists using a four-point scale.

Results: In human lung cancer and normal adjacent lung samples obtained from 34 lung cancer patients, MOR expression was increased significantly in cancer samples from patients with lung cancer compared with adjacent control tissue (P=0.0242). When the samples from patients with metastatic lung cancer were separated from the cohort of the total number of patients with lung cancer, we observed an approximately two-fold increase in MOR expression (P=0.0013).

Conclusions: The association between the expression of MOR and the progression of the tumour is consistent with the hypothesis of a direct effect of MOR on cancer progression.

Citing Articles

Opioid System and Epithelial-Mesenchymal Transition.

Lazarczyk M, Skiba D, Mickael M, Jaskula K, Nawrocka A, Religa P Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861181 PMC: 11768736. DOI: 10.3390/ph18010120.

Anesthetic Approaches and Their Impact on Cancer Recurrence and Metastasis: A Comprehensive Review.

Choi H, Hwang W Cancers (Basel). 2025; 16(24.

PMID: 39766169 PMC: 11674873. DOI: 10.3390/cancers16244269.

The Role of Anesthetic Management in Lung Cancer Recurrence and Metastasis: A Comprehensive Review.

Huh J, Hwang W J Clin Med. 2024; 13(22).

PMID: 39597826 PMC: 11594908. DOI: 10.3390/jcm13226681.

Anesthesia and cancer.

da Cunha Leal P, Albuquerque M, Diego L, Tardelli M Rev Assoc Med Bras (1992). 2024; 70(suppl 1):e2024S102.

PMID: 38865522 PMC: 11164268. DOI: 10.1590/1806-9282.2024S102.

Anesthesia and cancer recurrence: a narrative review.

Ahn H Anesth Pain Med (Seoul). 2024; 19(2):94-108.

PMID: 38725164 PMC: 11089301. DOI: 10.17085/apm.24041.

References

Zylla D, Gourley B, Vang D, Jackson S, Boatman S, Lindgren B . Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer. 2013; 119(23):4103-10. PMC: 3833881. DOI: 10.1002/cncr.28345. View

Afsharimani B, Cabot P, Parat M . Morphine use in cancer surgery. Front Pharmacol. 2011; 2:46. PMC: 3151591. DOI: 10.3389/fphar.2011.00046. View

Wang S, Li Y, Liu X, Zhao C, Yang K . Polymorphism of A118G in μ-opioid receptor gene is associated with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Clin Oncol. 2012; 18(4):666-9. DOI: 10.1007/s10147-012-0441-5. View

Christopherson R, James K, Tableman M, Marshall P, Johnson F . Long-term survival after colon cancer surgery: a variation associated with choice of anesthesia. Anesth Analg. 2008; 107(1):325-32. DOI: 10.1213/ane.0b013e3181770f55. View

Subramanian J, Madadi A, Dandona M, Williams K, Morgensztern D, Govindan R . Review of ongoing clinical trials in non-small cell lung cancer: a status report for 2009 from the ClinicalTrials.gov website. J Thorac Oncol. 2010; 5(8):1116-9. DOI: 10.1097/JTO.0b013e3181e76159. View

Tavare A, Perry N, Benzonana L, Takata M, Ma D . Cancer recurrence after surgery: direct and indirect effects of anesthetic agents. Int J Cancer. 2011; 130(6):1237-50. DOI: 10.1002/ijc.26448. View

Afsharimani B, Cabot P, Parat M . Morphine and tumor growth and metastasis. Cancer Metastasis Rev. 2011; 30(2):225-38. DOI: 10.1007/s10555-011-9285-0. View

Snyder G, Greenberg S . Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br J Anaesth. 2010; 105(2):106-15. DOI: 10.1093/bja/aeq164. View

Bortsov A, Millikan R, Belfer I, Boortz-Marx R, Arora H, McLean S . μ-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. Anesthesiology. 2012; 116(4):896-902. PMC: 3310356. DOI: 10.1097/ALN.0b013e31824b96a1. View

10.

Biki B, Mascha E, Moriarty D, Fitzpatrick J, Sessler D, Buggy D . Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology. 2008; 109(2):180-7. DOI: 10.1097/ALN.0b013e31817f5b73. View

11.

Mathew B, Lennon F, Siegler J, Mirzapoiazova T, Mambetsariev N, Sammani S . The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg. 2010; 112(3):558-67. PMC: 4327979. DOI: 10.1213/ANE.0b013e31820568af. View

12.

Singleton P, Moreno-Vinasco L, Sammani S, Wanderling S, Moss J, Garcia J . Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation. Am J Respir Cell Mol Biol. 2007; 37(2):222-31. DOI: 10.1165/rcmb.2006-0327OC. View

13.

Ganjoo K, Wakelee H . Review of erlotinib in the treatment of advanced non-small cell lung cancer. Biologics. 2009; 1(4):335-46. PMC: 2721286. View

14.

Lennon F, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J, Singleton P . Overexpression of the μ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology. 2012; 116(4):857-67. DOI: 10.1097/ALN.0b013e31824babe2. View

15.

Rastogi B, Gupta K, Rastogi A, Gupta P, Singhal A, Singh I . Hemiarthroplasty in high risk elderly patient under epidural anesthesia with 0.75% ropivacaine-fentanyl versus 0.5% bupivacaine-fentanyl: Clinical trial. Saudi J Anaesth. 2013; 7(2):142-5. PMC: 3737688. DOI: 10.4103/1658-354X.114058. View

16.

Singleton P, Moss J . Effect of perioperative opioids on cancer recurrence: a hypothesis. Future Oncol. 2010; 6(8):1237-42. DOI: 10.2217/fon.10.99. View

17.

Lennon F, Mirzapoiazova T, Mambetsariev B, Poroyko V, Salgia R, Moss J . The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. PLoS One. 2014; 9(3):e91577. PMC: 3963855. DOI: 10.1371/journal.pone.0091577. View

18.

Spiro S, Tanner N, Silvestri G, Janes S, Lim E, Vansteenkiste J . Lung cancer: progress in diagnosis, staging and therapy. Respirology. 2010; 15(1):44-50. DOI: 10.1111/j.1440-1843.2009.01674.x. View

19.

Carlson J . Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence. Expert Rev Pharmacoecon Outcomes Res. 2009; 9(5):409-16. DOI: 10.1586/erp.09.49. View

20.

Ng R, Loreto M, Lee R, Leighl N . Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy. Lung Cancer. 2008; 61(2):262-5. DOI: 10.1016/j.lungcan.2008.02.002. View